Treatment-induced neuropathy of diabetes: challenges in diagnosing neuropathic pain, value of sudomotor function testing.
Salim AbdelhamidMajlinda ShabaniArkadiusz RussjanAlexander Andrea TarnutzerPublished in: BMJ case reports (2023)
A patient in his 60s was admitted for an extensive neurological work-up due to progressive asymmetrical, distally pronounced pain in both feet and legs. Conventional pain relievers did not help in pain reduction. A Sudoscan revealed small fibre damage in all extremities indicating an underlying neuropathy. The patient had started insulin treatment around 6 months prior to hospitalisation because of a newly diagnosed late-onset diabetes. Due to a rapid drop in glycated haemoglobin (from over 14% to 6% in 4 months), treatment-induced neuropathy of diabetes (TIND) was hypothesised. On increasing the dose of pregabalin and adding duloxetine, the patient reported improvement of symptoms, which further underlined the suspected diagnosis. Hence, in patients with severe hyperglycaemia, changes in glycaemic control should be stepwise and not rapid; however, to date, no guidelines exist how to avoid TIND.
Keyphrases
- neuropathic pain
- type diabetes
- late onset
- chronic pain
- cardiovascular disease
- spinal cord
- glycemic control
- spinal cord injury
- newly diagnosed
- pain management
- early onset
- patient reported
- multiple sclerosis
- case report
- high glucose
- combination therapy
- drug induced
- diabetic rats
- endothelial cells
- metabolic syndrome
- postoperative pain
- depressive symptoms
- adipose tissue
- physical activity
- weight loss
- replacement therapy
- sensitive detection